Homeostasis: apoptosis and cell cycle in normal and pathological prostate

Figures & data

Table 1. Clinic pathological feacture of patients.

	Median (range)
Age (years)	66.00 (52–74)
Preoperative serum PSA (ng/ml)	11.35 (14–233)
	% (n)		% (n)
Preoperative serum PSA		Gleason score
<10 ng/ ml	36.0 (31)	≤6	81.4 (70)
≥10 ng/ml	64.0 (55)	>6	18.6 (16)
Clinical T stage		Pathological T stage
I	54.7 (47)	II	65.1 (56)
II	45.3 (39)	III	31.4 (27)
		IV	3.5 (3)
Perineural invasión (yes)	26.7 (23)	Node involvement (yes)	4.7 (4)
Positive surgical margins	38.4 (33)	Biochemical progression (yes)	33.7 (29)
Survival (yes)	73.3 (63)

Table 2. (A) Percentages of patients showing positive immunohistochemical reactions to all the antibodies studied in normal prostate (NP), (B) benign prostatic hyperplasia (BHP), (C) prostatic carcinoma (PC); and average optical densities (O.D.) of immunostainings in positive patients, (D) statistical frequence of patients positive for antibodies under study.

A	% (n)	NP O.D.	B	% (n)	BHP O.D.	C	% (n)	PC O.D.	D	P. Low % (n)	P. High % (n)
Bcl-2	35 (7)	4.87 ± 0.98^a	Bcl-2	35.7 (17)	9.87 ± 1.62^b	Bcl-2	69.8 (60)	10.56 ± 2.25^b	Bcl-2	38.4 (33)	31.4 (27)
Bcl-xL	100 (20)	17.26 ± 3.21	Bcl-xL	97.1 (34)	17.96 ± 2.7	Bcl-xL	75.6 (65)	15.6 ± 1.88	Bcl-xL	33.7 (29)	41.9 (36)
Mcl-1	40 (8)	11.6 ± 1.56^a	Mcl-1	28.6 (10)	13.8 ± 1.9^b	Mcl-1	86 (74)	18.76 ± 1.68^b	Mcl-1	17.4 (15)	68.6 (59)
Bax	50 (10)	6.22 ± 1.2^a	Bax	78.6 (26)	6.23 ± 1.73^a	Bax	48.8 (42)	11.21 ± 2.39^b	Bax	10.5 (9)	38.4 (33)
Bim	25 (5)	8.47 ± 2.89^a	Bim	71.4 (25)	20.50 ± 1.41^b	Bim	89.5 (77)	27.61 ± 4.16^c	Bim	48.8 (42)	40.7 (35)
Bad	20 (4)	8.02 ± 3.85^a	Bad	42.6 (6)	7.52 ± 2.68^a	Bad	59.3 (51)	21.1 ± 3.4^b	Bad	14.0 (12)	45.3 (39)
PUMA	75(15)	11.54 ± 1.6	PUMA	100 (35)	13.7 ± 0.8	PUMA	90.7 (78)	14.85 ± 1.8	PUMA	26.7 (23)	64.0 (55)
Noxa	100 (20)	5.25 ± 2.7	Noxa	97.1 (34)	4.92 ± 0.9	Noxa	96.5 (83)	5.94 ± 1.1	Noxa	31.4 (27)	65.1 (56)
p21	–	–	p21	100 (35)	35.81 ± 4.17^a	p21	84.9 (73)	49.07 ± 3.97^b	p21	27.9 (24)	57.0 (49)
p27	–	–	p27	77.0 (27)	5.85 ± 1.05	p27	58.1 (50)	9.03 ± 1.35	p27	53.5 (46)	4.7 (4)
Rb	–	–	Rb	35.7 (12)	34.27 ± 4.8^a	Rb	45.3 (39)	54.23 ± 7.07^b	Rb	37.2 (32)	8.1 (7)
pRb	–	–	pRb	71.4 (25)	11.98 ± 5.6^a	pRb	98.8 (85)	24.77 ± 6.74^b	pRb	4.7 (4)	94.2 (81)
mtp53	–	–	mtp53	100 (35)	8.67 ± 2.05^a	mtp53	90.7 (78)	13.92 ± 2.85^b	mtp53	20.9 (18)	69.8 (60)

Patients positive for immunohistochemistry were stratified according to the intensity of immunostaining in low positive and high positive. Average optical densities were evaluated only in patients showing positive immunoreactions. Statistical analysis refers to each antibody separately. Significance was determined by the one-way ANOVA test at p ≤ .05, by multiple pairwise comparisons. Superscript letters denote statistical significance: ***p < .05.

Figure 1. Expression of Bcl-2 (A–D), Bcl-xL (E,F), Mcl-1 (G,H), Bax (I,J), Bim (K,L), Bad (M,N) y PUMA (O,P) in normal prostate (A,H), BPH (B,E,G,K,M,O) and prostate cancer (C,D,F,H,J,L,N,P). Scale bars: 30 μm (O,P), 25 μm (A,B,G,I,J,K) and 20 μm (C,E,F,H,L,M,N), 15 μm (D).

Figure 2. Expression of Noxa (A,B), p27 (C,D), pRb (E,F), mp53 (G–I) in normal prostate (G), BPH (B,D,F,I) and prostate cancer (C–F). Scale bars: 25 μm (A,D,G,H,I) and 20 μm (B,C,E,F).

Table 3. Correlation expression of studied proteins and clinic pathological feature.

	Bcl-2		Bcl-xL		Mcl-1		Bax		Bim		Bad
	r	p	r	p	r	p	r	p	r	p	r	p
Preoperative serum PSA	0.033	0.762	0.081	0.491	−0.023	0.835	0.055	0.614	−0.098	0.367	−0.030	0.781
Pathological T stage	0.071	0.516	−0.042	0.702	0.090	0.409	0.165	0.128	0.068	0.534	−0.003	0.975
Clinical T stage	−0.112	0.303	0.083	0.445	−0.038	0.731	−0.002	0.984	0.086	0.450	0.041	0.705
Gleason score	−0.076	0.489	−0.076	0.487	−0.066	0.545	0.071	0.517	−0.032	0.771	0.092	0.400
Perineural invasion	−0060	0.584	0.038	0.730	−0.060	0.583	−0.012	0.911	0.121	0.268	−0.034	0.755
Node involvement	−0.095	0.384	−0.003	0.978	0.089	0.415	0.116	0.289	−0.105	0.337	−0.042	0.702
Positive surgical margins	0.155	0.154	−0.052	0.632	0.180	0.098	−0.006	0.959	−0.043	0.696	−0.076	0.484
Biochemical progression	−0.173	0.111	−0.110	0.314	0.003	0.976	0.041	0.706	0.003	0.980	−0.160	0.141
Survival	0.055	0.618	−0.207	0.056	−0.136	0.213	−0.012	0.911	−0.137	0.209	−0.034	0.755

Table

	PUMA		Noxa		p21		p27		Rb		pRb		mtp53
	r	p	r	p	r	p	r	p	r	p	r	p	r	p
Preoperative serum PSA	−0.074	0.500	−0.143	0.190	0.021	0.846	−0.146	0.179	−0.094	0.387	−0.081	0.456	0.010	0.929
Pathological T stage	−0.009	0.937	0.011	0.922	0.022	0.841	0.143	0.190	−0.005	0.967	−0.139	0.202	0.072	0.512
Clinical T stage	−0.110	0.312	−0.081	0.456	−0.137	0.208	0.252	0.019	−0.032	0.769	−0.119	0.275	0.050	0.644
Gleason score	−0.053	0.630	−0.072	0.510	−0.048	0.657	−0.079	0.470	−0.195	0.071	0.052	0.635	0.153	0.159
Perineural invasion	0.103	0.345	−0.171	0.114	0.045	0.683	0.087	0.427	−0.128	0.239	0.066	0.549	0.103	0.345
Node involvement	−0.119	0.274	0.042	0.701	0.046	0.673	0.075	0.490	−0.201	0.063	0.024	0.827	0.071	0.518
Positive surgical margins	0.080	0.420	0.150	0.168	0.014	0.902	0.039	0.718	0.050	0.649	−0.137	0.207	0.088	0.420
Biochemical progression	0.059	0.589	−0.132	0.224	0.095	0.384	0.007	0.949	−0.057	0.603	0.077	0.479	0.144	0.187
Survival	−0.078	0.476	−0.028	0.796	−0.021	0.850	−0.126	0.246	−0.023	0.836	0.066	0.549	0.194	0.074

Bold values indicate significant p < .05.

Table 4. Correlation between immunohistochemical score of studied proteins and clinic pathological feature.

	Bcl-2		Bcl-xL		Mcl-1		Bax		Bim		Bad
	r	p	r	p	r	p	r	p	r	p	r	p
Preoperative serum PSA	0.073	0.504	0.138	0.204	−0.170	0.118	0.076	0.487	−0.092	0.400	−0.041	0.707
Pathological T stage	0.078	0.473	0.069	0.526	−0.032	0.770	0.152	0.163	0.092	0.398	−0.073	0.501
Clinical T stage	−0.253	0.019	−0.005	0.963	0.044	0.686	−0.001	0.996	0.114	0.295	0.003	0.978
Gleason score	−0.045	0.682	−0.023	0.837	−0.014	0.898	0.094	0.387	−0.037	0.733	0.105	0.335
Perineural invasion	−0.076	0.487	0.031	0.776	0.045	0.683	0.022	0.842	0.026	0.814	0.029	0.792
Node involvement	−0.144	0.185	0.101	0.354	0.046	0.673	0.145	0.184	−0.191	0.078	−0.010	0.929
Positive surgical margins	0.079	0.471	−0.118	0.277	0.014	0.902	−0.018	0.868	−0.156	0.152	−0.092	0.402
Biochemical progression	−0.199	0.067	−0.159	0.144	0.095	0.384	0.045	0.683	0.009	0.932	−0086	0.433
Survival	0.058	0.596	−0.266	0.013	−0.021	0.850	−0.028	0.800	−0.064	0.559	−0.060	0.586

Table

	PUMA		Noxa		p21		p27		Rb		pRb		mtp53
	r	p	r	p	r	p	r	p	r	p	r	p	r	p
Preoperative serum PSA	−0.068	0.531	−0.010	0.927	0.113	0.300	−0.179	0.100	−0.095	0.386	−0.084	0.441	0.126	0.248
Pathological T stage	0.223	0.039	−0.053	0.629	0.084	0.440	0.147	0.177	0.026	0.809	−0.157	0.149	−0.014	0.899
Clinical T stage	−0.021	0.847	−0.029	0.788	0.028	0.801	0.265	0.014	0.009	0.934	−0.075	0.490	−0.182	0.094
Gleason score	0.031	0.775	−0.215	0.047	0.029	0.790	0.064	0.556	−0.209	0.053	−0.007	0.946	−0.039	0.723
Perineural invasion	0.036	0.741	−0.180	0.097	0.071	0.517	0.108	0.321	−0.112	0.306	−0.072	0.511	0.068	0.533
Node involvement	−0.083	0.449	0.160	0.140	−0.044	0.689	0.058	0.595	−0.196	0.071	−0178	0.101	−0.072	0.512
Positive surgical margins	0.103	0.346	−0.003	0.975	−0.052	0.634	0.049	0.652	0.072	0.508	−0.012	0.914	0.109	0.319
Biochemical progression	0.124	0.253	−0.111	0.310	−0.136	0.212	−0.003	0.975	−0.081	0.461	−0.031	0.780	0.016	0.884
Survival	−0.051	0.640	0.050	0.646	−0.082	0.452	−0.119	0.275	−0.041	0.710	0.039	0.720	−0.017	0.876

Bold values indicate significant p < .05.

Data availability

All data generated or analyzed during this study are included in this published article.